{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:20:30Z","timestamp":1787988030890,"version":"build-2784847793"},"reference-count":30,"publisher":"Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,12,1]]},"abstract":"<jats:p>Abstract: Background: The biology of the estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancers is heterogeneous even when they are categorized by their risk via genomics. Transcriptomic PGR expression reflects endocrine pathway activity and may provide complementary biological information within established GENE70-derived genomic-risk categories. Whether this molecular marker improves the biological interpretation of genomic-risk stratification beyond conventional clinicopathological assessment remains uncertain. Objectives: The aim of this study was to determine whether transcriptomic PGR expression provides complementary biological and prognostic information within reconstructed GENE70-derived genomic-risk categories and refines the characterization of endocrine-related tumour biology in ER-positive\/HER2-negative breast cancer. Methods: This study analysed publicly available transcriptomic and clinical data from three cohorts: METABRIC (discovery cohort), GSE96058\/SCAN-B cohort (validation cohort) and TCGA-BRCA cohort (molecular validation cohort). The GENE70-derived genomic-risk score was reconstructed for each cohort using matched genes. Cox regression, Kaplan-Meier analysis and subgroup comparisons were used to assess relationships between PGR expression, clinicopathologic variables, molecular features and survival outcomes. Results: Across the three independent cohorts, low transcriptomic PGR expression was consistently associated with higher GENE70-derived genomic risk, increased MKI67 expression, reduced ESR1 expression and enrichment of the Luminal B subtype. Survival findings differed between cohorts. In the discovery METABRIC cohort, transcriptomic PGR expression showed heterogeneous associations with survival, particularly within GENE70-derived high-risk subgroups, whereas the external GSE96058\/SCAN-B validation cohort demonstrated consistent associations between low PGR expression and poorer overall survival in both the overall ER-positive\/HER2-negative population and GENE70-derived high-risk subgroups. Conclusion: These findings suggest that transcriptomic PGR provides complementary biological and prognostic information within GENE70-derived genomic-risk categories. However, because treatment response was not evaluated in the present study, the findings should not be interpreted as evidence of predictive or pharmacogenomic utility and prospective studies incorporating treatment-response analyses are required before such applications can be established.<\/jats:p>","DOI":"10.36721\/pjps.2026.39.12.331.1","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T11:48:01Z","timestamp":1787485681000},"source":"Crossref","is-referenced-by-count":0,"title":["PGR expression as a pharmacogenomic companion biomarker to GENE70-derived genomic risk in ER-positive\/HER2-negative breast cancer"],"prefix":"10.36721","author":[{"given":"Orcun","family":"Can","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22735","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"key":"ref0","unstructured":"Allison KH and Rendi MH (2022). Updates on breast biomarkers. Virchows Arch., 480(3): 453-468."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM and Wolff AC (2020). Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J. Clin. Oncol., 38(12): 1346-1366.","DOI":"10.1200\/JCO.19.02309"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC and Stearns V (2022). Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J. Clin. Oncol., 40(16): 1816-1837.","DOI":"10.1200\/JCO.22.00069"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garcia Saenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortes J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG and Bardia A (2022). Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J. Clin. Oncol., 40(28): 3246-3256.","DOI":"10.1200\/JCO.22.00338"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A (2024). Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 74(3): 229-263.","DOI":"10.3322\/caac.21834"},{"key":"ref5","unstructured":"Burstein HJ, Curigliano G, Thurlimann B, Weber WP, Poortmans P, Regan MM, Senn HJ, Winer EP and Gnant M (2021). Customizing local and systemic therapies for women with early breast cancer: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann. Oncol., 32(10): 1216-1235."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E and Piccart M (2016). 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N. Engl. J. Med., 375(8): 717-729.","DOI":"10.1056\/NEJMoa1602253"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Drukker CA, Bueno-de-Mesquita JM, Retel VP, van Harten WH, Tinteren HV, Wesseling J, Rutgers EJT, van de Vijver MJ and van't Veer LJ (2013). A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int. J. Cancer, 133(4): 929-936.","DOI":"10.1002\/ijc.28082"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A and Siegel RL (2024). Breast cancer statistics, 2024. CA Cancer J. Clin., 74(6): 477-495.","DOI":"10.3322\/caac.21863"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Hanker AB, Sudhan DR and Arteaga CL (2020). Overcoming endocrine resistance in breast cancer. Cancer Cell, 37(4): 496-513.","DOI":"10.1016\/j.ccell.2020.03.009"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F (2019). Breast cancer. Nat. Rev. Dis. Primers, 5(1): 66.","DOI":"10.1038\/s41572-019-0111-2"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC and DeMichele A (2022). Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J. Clin. Oncol., 40(27): 3205-3221.","DOI":"10.1200\/JCO.22.01063"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Horwitz KB and Sartorius CA (2008). Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: A hypothesis. J. Clin. Endocrinol. Metab., 93(9): 3295-3298.","DOI":"10.1210\/jc.2008-0938"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Garnica Jaliffe G, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B andr\u00e9 V, Harbeck N and Martin M (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): Results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol., 24(1): 77-90.","DOI":"10.1016\/S1470-2045(22)00694-5"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, Dhesy-Thind S, Rastogi P, Alba E, Delaloge S, Martin M, Kelly CM, Ruiz-Borrego M, Gil-Gil M, Arce-Salinas CH, Brain EGC, Lee ES, Pierga JY, Bermejo B, Ramos-Vazquez M, Jung KH, Ferrero JM, Schott AF, Shak S, Sharma P, Lew DL, Miao J, Tripathy D, Pusztai L and Hortobagyi GN (2021). 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N. Engl. J. Med., 385(25): 2336-2347.","DOI":"10.1056\/NEJMoa2108873"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lloyd MR, Jhaveri K, Kalinsky K, Bardia A and Wander SA (2024). Precision therapeutics and emerging strategies for hormone receptor-positive metastatic breast cancer. Nat. Rev. Clin. Oncol., 21: 743-761.","DOI":"10.1038\/s41571-024-00935-6"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Loibl S andre F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, Cardoso MJ, Carey LA, Dawood S, Del Mastro L, Denkert C, Fallenberg EM, Francis PA, Gamal-Eldin H, Gelmon K, Geyer CE, Gnant M, Guarneri V, Gupta S, Kim SB, Krug D, Martin M, Meattini I, Morrow M, Janni W, Paluch-Shimon S, Partridge A, Poortmans P, Pusztai L, Regan MM, Sparano J, Spanic T, Swain SM, Tjulandin S, Toi M, Trapani D, Tutt A, Xu B and Curigliano G (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol., 35(2): 159-182.","DOI":"10.1016\/j.annonc.2023.11.016"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca F, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M and Hayes DF (2021). Assessment of Ki67 in breast cancer: Updated recommendations from the International Ki67 in Breast Cancer Working Group. J. Natl. Cancer Inst., 113(7): 808-819.","DOI":"10.1093\/jnci\/djaa201"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM and Bernard PS (2009). Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol., 27(8): 1160-1167.","DOI":"10.1200\/JCO.2008.18.1370"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, L\u00f8nning PE, B\u00f8rresen-Dale AL, Brown PO and Botstein D (2000). Molecular portraits of human breast tumours. Nature, 406(6797): 747-752.","DOI":"10.1038\/35021093"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Piccart M, van 't Veer LJ, Poncet C, Cardoso F, Delaloge S, Pierga JY, Vuylsteke P, Nitz U, Pusztai L, Saghatchian M, Forbes J, Tryfonidis K, Liti\u00e8re S, Aftimos P, Bolla M, Bogaerts J and Rutgers E (2021). 70-gene signature as an aid for treatment decisions in early breast cancer: Updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol., 22(4): 476-488.","DOI":"10.1016\/S1470-2045(21)00007-3"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Prat A, Cheang MCU, Mart\u00edn M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO and Perou CM (2013). Prognostic significance of progesterone receptor-positive tumour cells within immunohistochemically defined luminal A breast cancer. J. Clin. Oncol., 31(2): 203-209.","DOI":"10.1200\/JCO.2012.43.4134"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Purdie CA, Quinlan P, Jordan LB, Ashfield A, Ogston S, Dewar JA and Thompson AM (2014). Progesterone receptor expression is an independent prognostic variable in early breast cancer: A population-based study. Br. J. Cancer, 110(3): 565-572.","DOI":"10.1038\/bjc.2013.756"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Ruiz-Borrego M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Afenjar K, Fresco R, Severin I, Ji Y, Ghaznawi F, Li Z, Zarate JP, Chakravartty A, Taran T and Hortobagyi GN (2024). Ribociclib plus endocrine therapy in early breast cancer. N. Engl. J. Med., 390(12): 1080-1091.","DOI":"10.1056\/NEJMoa2305488"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"S\u00f8rlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, L\u00f8nning PE and B\u00f8rresen-Dale AL (2001). Gene expression patterns of breast carcinomas distinguish tumour subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A., 98(19): 10869-10874.","DOI":"10.1073\/pnas.191367098"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J and Sledge GW Jr (2018). Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N. Engl. J. Med., 379(2): 111-121.","DOI":"10.1056\/NEJMoa1804710"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J and Sledge GW Jr (2019). Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N. Engl. J. Med., 380(25): 2395-2405.","DOI":"10.1056\/NEJMoa1904819"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490(7418): 61-70.","DOI":"10.1038\/nature11412"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balma\u00f1a J, Domchek SM, Gelmon KA, Hollingsworth SJ, Korde LA, Linderholm B, Bandos H, Senkus E, Suga JM, Shao Z, Pippas AW, Nowecki Z, Huzarski T, Ganz PA, Lucas PC, Baker N, Loibl S, McConnell R, Piccart M, Schmutzler R, Steger GG, Costantino JP, Arahmani A, Wolmark N, McFadden E, Karantza V, Lakhani SR, Yothers G, Campbell C and Geyer CE Jr (2021). Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med., 384(25): 2394-2405.","DOI":"10.1056\/NEJMoa2105215"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A and Rugo HS (2023). Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med., 388(22): 2058-2070.","DOI":"10.1056\/NEJMoa2214131"}],"container-title":["Pakistan Journal of Pharmaceutical Sciences"],"original-title":[],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:53:34Z","timestamp":1787986414000},"score":1,"resource":{"primary":{"URL":"https:\/\/pjps.pk\/single-article?id=7942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":30,"URL":"https:\/\/doi.org\/10.36721\/pjps.2026.39.12.331.1","relation":{},"ISSN":["1011-601X","3105-9686"],"issn-type":[{"value":"1011-601X","type":"print"},{"value":"3105-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]}}}